Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients and leads to a significant increase in health care costs. Cancer patients often suffer from multiple co-morbidities and have both a greater risk of VTE recurrence and bleeding compared to non-cancer patients...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/11/1/71 |
| _version_ | 1797715606659661824 |
|---|---|
| author | Corinne Frere Ilham Benzidia Zora Marjanovic Dominique Farge |
| author_facet | Corinne Frere Ilham Benzidia Zora Marjanovic Dominique Farge |
| author_sort | Corinne Frere |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients and leads to a significant increase in health care costs. Cancer patients often suffer from multiple co-morbidities and have both a greater risk of VTE recurrence and bleeding compared to non-cancer patients. Anticoagulation is therefore challenging. For many years, long-term therapy with Low-Molecular-Weight Heparin (LMWH) was the standard of care for the management of cancer-associated VTE. Direct oral anticoagulants (DOAC), which offer the convenience of an oral administration and have a rapid onset of action, have recently been proposed as a new option in this setting. Head-to-head comparisons between DOAC and LMWHs for the treatment of established VTE are now available, and data on the efficacy and safety of these drugs for primary prophylaxis of VTE in ambulatory cancer patients receiving systemic anticancer therapy are emerging. This narrative review aims to summarize the main recent advances in the prevention and treatment of cancer-associated VTE, including recent data on the use of individualized factors to stratify the risk of VTE in each individual patient, quality-of-life in patients treated with LMWH, and the place that DOACs will likely take in the cancer-associated VTE management landscape. |
| first_indexed | 2024-03-12T08:09:15Z |
| format | Article |
| id | doaj.art-e0e55cf02d79478eb271a5cba205b937 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T08:09:15Z |
| publishDate | 2019-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-e0e55cf02d79478eb271a5cba205b9372023-09-02T19:18:10ZengMDPI AGCancers2072-66942019-01-011117110.3390/cancers11010071cancers11010071Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New ChallengesCorinne Frere0Ilham Benzidia1Zora Marjanovic2Dominique Farge3Institute of Cardiometabolism And Nutrition, INSERM UMRS_1166, Sorbonne Université, F-75013 Paris, FranceAutoimmune and Vascular Disease Unit, Internal Medicine (UF04), Center of reference for rare systemic autoimmne diseases (FAI2R), Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, F-75010 Paris, FranceDepartment of Haematology, Saint-Antoine Hospital, Assistance Publique Hôpitaux de Paris, F-75012 Paris, FranceAutoimmune and Vascular Disease Unit, Internal Medicine (UF04), Center of reference for rare systemic autoimmne diseases (FAI2R), Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, F-75010 Paris, FranceVenous thromboembolism (VTE) is a common cause of morbidity and mortality in cancer patients and leads to a significant increase in health care costs. Cancer patients often suffer from multiple co-morbidities and have both a greater risk of VTE recurrence and bleeding compared to non-cancer patients. Anticoagulation is therefore challenging. For many years, long-term therapy with Low-Molecular-Weight Heparin (LMWH) was the standard of care for the management of cancer-associated VTE. Direct oral anticoagulants (DOAC), which offer the convenience of an oral administration and have a rapid onset of action, have recently been proposed as a new option in this setting. Head-to-head comparisons between DOAC and LMWHs for the treatment of established VTE are now available, and data on the efficacy and safety of these drugs for primary prophylaxis of VTE in ambulatory cancer patients receiving systemic anticancer therapy are emerging. This narrative review aims to summarize the main recent advances in the prevention and treatment of cancer-associated VTE, including recent data on the use of individualized factors to stratify the risk of VTE in each individual patient, quality-of-life in patients treated with LMWH, and the place that DOACs will likely take in the cancer-associated VTE management landscape.http://www.mdpi.com/2072-6694/11/1/71venous thromboembolismcancerlow molecular weight heparindirect oral anticoagulant |
| spellingShingle | Corinne Frere Ilham Benzidia Zora Marjanovic Dominique Farge Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges Cancers venous thromboembolism cancer low molecular weight heparin direct oral anticoagulant |
| title | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
| title_full | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
| title_fullStr | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
| title_full_unstemmed | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
| title_short | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
| title_sort | recent advances in the management of cancer associated thrombosis new hopes but new challenges |
| topic | venous thromboembolism cancer low molecular weight heparin direct oral anticoagulant |
| url | http://www.mdpi.com/2072-6694/11/1/71 |
| work_keys_str_mv | AT corinnefrere recentadvancesinthemanagementofcancerassociatedthrombosisnewhopesbutnewchallenges AT ilhambenzidia recentadvancesinthemanagementofcancerassociatedthrombosisnewhopesbutnewchallenges AT zoramarjanovic recentadvancesinthemanagementofcancerassociatedthrombosisnewhopesbutnewchallenges AT dominiquefarge recentadvancesinthemanagementofcancerassociatedthrombosisnewhopesbutnewchallenges |